3 completed, 3 terminated, 1 enrolling by invitation, 1 recruiting. 5 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Terminated 2 |
| Phase 2 | 5 | Terminated 2, Completed 1, Enrolling by invitation 1, Recruiting 1 |
Follow Inmagene LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis IMG-007 - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Enrolling by invitation | Inmagene LLC | 400 | 2026-06-05 | 2026-07-29 |
| A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis IMG-007, Placebo - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Recruiting | Inmagene LLC | 405 | 2025-06-17 | 2026-08-12 |
| Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants IMG-007, Placebo - Healthy Volunteers | Phase 1 | Terminated | Inmagene LLC | 16 | 2024-03-06 | 2024-12-12 |
| A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants IMG-007 - Alopecia Areata (AA) | Phase 1 / Phase 2 | Completed | Inmagene LLC | 29 | 2023-09-25 | 2026-02-09 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) Placebo, IMG-007 - Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | Phase 1 / Phase 2 | Terminated | Inmagene LLC | 13 | 2023-08-09 | 2025-11-06 |
| Study to Evaluate IMG-004 in Healthy Participants SAD IMG-004 30mg, SAD IMG-004 100mg, SAD IMG-004 200mg - Healthy Participants | Phase 1 | Completed | Inmagene LLC | 72 | 2022-08-08 | 2024-05-17 |
| Evaluate IMG-007 in Healthy Participants IMG-007 or placebo - Healthy Participants | Phase 1 | Completed | Inmagene LLC | 44 | 2022-07-05 | 2023-06-28 |
| ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis ABY-035, Placebo - Ankylosing Spondylitis | Phase 2 | Terminated | Inmagene LLC | 25 | 2021-08-24 | 2023-07-12 |
Immune System Diseases (4) · Skin Diseases (4) · Dermatitis (3) · Dermatitis, Atopic (3) · Eczema (3) · Alopecia (1) · Alopecia Areata (1) · Spondylitis, Ankylosing (1)
Saline Solution (1)
United States (6) · Canada (4) · Australia (3) · China (1) · New Zealand (1) · South Korea (1)
Lawrence He (1) · Peter Schrader (1)